Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma

Ovarian clear cell carcinoma (OCCC) is an aggressive neoplasm with a high recurrence rate that frequently develops resistance to platinum-based chemotherapy. There are few prognostic biomarkers or targeted therapies exist for patients with OCCC. Here, we identified that FXYD2, the modulating subunit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Hsu, I-Ling, Chou, Cheng-Yang, Wu, Yi-Ying, Wu, Jia-En, Liang, Chen-Hsien, Tsai, Yao-Tsung, Ke, Jhen-Yu, Chen, Yuh-Ling, Hsu, Keng-Fu, Hong, Tse-Ming
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2016
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5325337/
https://ncbi.nlm.nih.gov/pubmed/26910837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7497
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge